We understand how distressing and debilitating immune-mediated inflammatory diseases (IMIDs) can be, which is why we strive to provide treatments that give you or your loved ones relief from the daily discomfort and stress that these conditions can pose. Rest assured, we are committed to building on our breakthroughs that have already changed the lives of millions of people around the world.
Our commitment to patients
Janssen is committed to helping ease the battle that people living with immune-mediated inflammatory diseases have to endure for the rest of their lives.
Our goal at Janssen is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
We never underestimate the human impact of immune-mediated inflammatory diseases
People living with immune-mediated inflammatory diseases can face a lifetime of managing their condition, yet the impact of these diseases is dramatically underestimated. As some of these diseases are not readily recognised, people can suffer silently before eventually receiving treatment.
Immune-mediated inflammatory diseases are the result of a relentless, internal, immunological ‘storm’, which can cause pain and discomfort that many people live with every day, , . People may experience stigma, isolation, decreased productivity and psychological issues, , , , . And it’s not just them, their families and loved ones can be affected too .
Our mission is clear: we won’t rest until we achieve a world free from immune-mediated inflammatory diseases.
Our Treatment Areas
We are proud to have one of the strongest treatment portfolios for some of the most common immune-mediated inflammatory diseases.
Our focus areas are:
Our focus in Rheumatology is currently inflammatory disorders of the joints and skin.Psoriatic arthritis
- Almost 1 in every 10 people in Europe are living with an immune-mediated inflammatory disease.
- Immune-mediated inflammatory diseases affect approximately 56-70 million people in Europe – and this number is rising. 
- Living with an immune-mediated inflammatory disease has a similar impact on psychological and physical functioning to cancer, heart disease and hypertension.,
- They are debilitating, chronic and potentially even fatal. Pain, fatigue and inability to perform everyday tasks are the most apparent symptoms.,, , , , , 
- Many people also suffer from severe additional conditions as a result, such as depression.,, ,
Janssen’s pioneering breakthroughs change lives
We’ve always been innovative in our science, finding new and more effective ways to transform the course of immune-mediated inflammatory diseases and calm the inner battle waging within patients’ bodies.
Since the advent of targeted biologic therapy over 30 years ago, we developed the first licensed monoclonal antibody to act directly on the immune system, providing patients with an unprecedented level of efficacy and symptomatic relief.
Our breakthroughs have changed the lives of millions of people around the world living with some of the most common immune-mediated inflammatory diseases.
We will continue our search for newer and better medicines
We’ve continued to advance our knowledge of the inflammatory process. We were the first again to develop treatments that intercept new pathways, which can substantially improve patients’ lives.
We’ll carry on working on better therapies to stop and even cure immune-mediated inflammatory diseases. Our world-class immunology pipeline includes numerous exciting first-in-class therapies. Many of them are for particularly difficult-to-treat indications, where the impact on patients is high and/or where there remains a need for better treatments.
Working together to achieve a world where immune-mediated inflammatory diseases are a thing of the past
Our commitment to immune-mediated inflammatory diseases goes beyond our medicines. We support patients through collaborations with patient advocacy organisations.
We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
We also bring together the brightest minds, including doctors, nurses, patients and patient groups, scientists and policy makers to turn scientific discoveries into treatment breakthroughs, and to ensure that people can benefit from the best treatments when they need them.Learn more about Janssen collaborations
We are for the PEACE Within
The PEACE Within represents our commitment to supporting people living with immune-mediated inflammatory diseases. Every member of our Janssen team is striving to bring the PEACE Within to people living with immune-mediated inflammatory diseases.
Through our unceasing research, we continue to improve our understanding of the immune system, and to discover and develop better treatments.
My IBD Journey
Looking for practical tips on living with inflammatory bowel disease (IBD)? Head to the My IBD Journey page, where you will find a series of short animations providing helpful advice about living well with IBD. These animations have been developed in association with the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA).MY IBD JOURNEY
If you want to learn more about psoriasis or psoriatic arthritis, check out Beyond Expectations, our online patient portal for people living with psoriatic disease or who are interested in learning more about the disease and treatment options..Beyond Expectations
 Lofvendahl, S., et al. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? Journal of Rheumatology, 2016;43(3):640-647
 Lonffors, S., et al. IBD and health-related quality of life - discovering the true impact. Journal of Crohn's and Colitis, 2014;8:1281-1286
 Najafi, S., et al. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol, 2020;39:3223–3235
 Eghlileb, A.M., et al. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol, 2007;156(6):1245-50
 Dibley, L., et al. The experience of stigma in inflammatory bowel disease: An interpretive (hermeneutic) phenomenological study. J Adv Nurs, 2018;74:838-851
 Ograczyk, A., et al. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatologi Alergologii, 2014;5:299-304
 Narayanan, S., et al. 2014. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl), 2014;5:1-7
 Cooper, G.S., et al. Recent Insights in the Epidemiology of Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases. J Autoimmun. 2009;33(3-4):197-207
 Mease P. Assessing impact of Psoriatic Arthritis on Patient Function and Quality of Life: Lessons Learned from Other Rheumatologic Conditions. Semin Arthritis Rheum, 2009;38(4):320-335
 Walker, J., Littlejohn, G. Measuring quality of life in Rheumatic conditions. Clin Rheumatol, 2017; 26,p:671-673
 Lupus Foundation of America. Lupus facts and statistics. 2016. Available at: https://www.lupus.org/resources/lupus-facts-and-statistics. Accessed: March 2022
 Scotti, L., et al. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arth Rheum. 2018;48:28-34
 Bacconier, L., et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. Rheumatology (Oxford) 2015;54(3):520-7
 Pompili, M., et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(IS):61-66
 Amador-Patarroyo. M.J., et al. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis, 2012;251730
 Habibi, F., et al. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci, 2017;22:104
 Becker, H.M., et al. Living with inflammatory bowel disease: A Crohn’s and Colitis Canada survey. Can J Gastroenterol Hepatol, 2015;29(2):77-84
 Shah, K., et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open, 2017;3(2):3
 Bernstein, C.N., et al. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(2):360-368
 Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116
 JNJ. Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration. 2017. Available at: https://jnj.brightspotcdn.com/1d/d2/b2f30f3f4625952a9fc84e473fc5/jnj-pipeline-4q2016.pdf. Accessed: March 2022
 EFCCA. My IBD Journey – animation series. 2019. Available at: http://www.efcca.org/en/projects/my-ibd-journey-animation-series. Accessed: March 2022